Drug intelligence / Profile preview

BRKB-500

Development stage: Unknown
Lead developer: BrickBio
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BRKB-500 is an antibody-drug conjugate (ADC) under development by BrickBio. As an ADC, it consists of a monoclonal antibody linked to a cytotoxic agent, designed to selectively deliver the cytotoxic payload to target cells expressing a specific antigen. The precise target antigen and payload for BRKB-500 have not been disclosed publicly as of June 2025. The drug is currently in the discovery phase and has not yet entered clinical trials or received regulatory approval. Its primary developer and active organization is BrickBio.

Beyond the preview

Go deeper on BRKB-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRKB-500.

Explore the full profile